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The  Ch~diak-Higashi syndrome (CHS)  is  a  rare disorder,  characterized by 
giant granules in most granule-containing cells. Its major clinical expression is 
a  marked susceptibility to pyogenic infections which, in the absence of defects 
in humoral or cellular immunity, has directed attention to polymorphonuclear 
leukocytes (PMNs).  The  properties  of CHS  PMNs  include  abnormally large 
azurophile  granules  (1),  somewhat  reduced  levels  of  /3-glucuronidase  and 
myeloperoxidase (35-50%  of normal) (2),  defects in chemotactic responses (3), 
and low bactericidal activity against some gram-positive microorganisms (4). 
Many of these defects, including those in PMNs, have also been found in animal 
models such as the beige mouse (bg/bg)  (5),  mink,  cattle  (6),  cats  (7),  and a 
killer whale  (8),  but  no  specific molecular defect that  could account for the 
enhanced sensitivity to bacterial infections has been identified. 
We recently found that fibrinolysis by human PMNs is due to the combined 
effects of plasminogen activator and elastase  (9). Since elastase is localized in 
azurophile granules (10), the abnormality of these organelles in C HS leukocytes 
prompted us to assay for this enzyme. The results show that leukocyte elastase 
is  either very low  or  undetectable  in  CHS  patients,  and  the  corresponding 
murine protease is profoundly decreased in leukocytes of beige mice. 
Materials and Methods 
Materials.  NCS mice were obtained from the stock maintained at The Rockefeller University; 
BALB/cJ and C57 BL/6J from  The Jackson Laboratory, Bar Harbor, Maine; and C57 BL/6J bg/bg 
were the generous gift  of Dr. J. Oliver at the University of Connecticut  Health Center, 
Farmington, Conn. Plasmagel was obtained from Roger Bellon Laboratories,  Paris,  France. The 
sources of  all  other materials were as described  previously (9). 
Case Histories 
The patients described below have been studied at the HSpital des Enfants Malades, Paris, and 
were in the care of one of the authors (C. G.). 
CHS CASE NO. 1.  5-yr-old female, with frequent Staphylococcus aureus infections. Leukocytes: 
3,200 per mmS; 50% neutrophils, 99% with abnormal granules; bactericidal activity (11) decreased 
against S. aureus, normal against Serratia marcescens. Not in accelerated phase of the disease, no 
treatment. 
CHS CAS~. NO. 2.  4-yr-old female, rare S. aureus infections. Leukocytes: 4,200 per mm3; 55% 
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neutrophils, 66% with abnormal granules; bactericidal activity decreased against S. aureus and 
Escherichia coli. Not in accelerated phase, no treatment. 
CHS CASE NO. 3.  5-yr-old male, frequent Neisseria and Candida albicans infections. Leuko- 
cytes: 3,300 per mm  3, 55% neutrophils, 100% abnormal granules; bactericidal activity decreased 
against S.  aureus,  normal against S.  marcescens.  Not in accelerated phase of the disease,  no 
treatment. 
Preparation of Cells 
HUMAN.  Human leukocytes were prepared by dextran or plasmagel sedimentation (1 h, 37°C) 
of heparinized (2 U/ml) venous blood.  The plasma containing leukocytes was collected, the cells 
were washed twice by centrifugation (300 g, 5 min) and resuspended in phosphate-buffered saline 
(PBS).  Cells  were  counted  in  Tiirk's  solution,  and  also  stained  with  Giemsa  for differential 
counting.  After final centrifugation, the pellet was frozen, stored at  -80°C,  and transported in 
dry ice. The cells were thawed and resuspended in PBS containing 0.5% Triton X-100, at 1.5 ×  107 
PMNs/ml, the lysate was vortexed, centrifuged (1,000 g, 10 min), and the supernate was assayed 
for fibrinolytic activity. 
MOUSE.  Peritoneal cells were collected by lavage with PBS 16 h after intraperitoneal injection 
of 30-ftg endotoxin (S. Minnesota LPS MR 595-$391) in 1 ml PBS. After washing in PBS, the cells 
were stained and counted. The yield for all strains tested was 6-10 ×  10  e cells per mouse; 80-85% 
were PMNs,  10% were macrophages, and 5-10% were lymphocytes. The cells (10~/ml) were lysed 
in PBS containing 0.25% Triton X-100, and the lysate was assayed directly,  or after dilution in 
PBS.  Alternatively,  cells  (107/ml)  were  lysad  in  PBS-0.25%  Triton  X-100,  the  lysate  was 
centrifuged (1,000 g,  10 min), and the activity of the supernate was analyzed by sodium dodecyl 
sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) (9). 
Assay for Fibrinolytic Activity.  ~sI-fibrin-coated wells of Linbro plates (Linbro Scientific Inc., 
Hamden, Conn.) were prepared as described elsewhere (9). Each well contained ----20 ~g 12~I-fibrin 
(5,000 cpm/~g).  The fibrinolytic activity of mouse cells was measured by adding 1 ml of lysates 
into 125I-fbrin coated wells and measuring the percentage of total radioactivity solubilized during 
2 h  of incubation at 37°C. 
Elastase activity was determined as follows: aliquots (5-50 ~1) of human leukocyte lysate or 
purified  porcine  pancreatic  elastase  (0.2  U/ml;  72.7  U/mg,  Worthington  Biochemical  Corp., 
Freehold, N. J.) were added to 125I-fibrin-coated wells containing 250 ~1 0.1 M Tris-C1, pH 8.1; the 
rate  of fibrinolysis  was  determined  by  measuring  the  radioactivity  solubilized  at  37°C  as  a 
function of time. Under these conditions, the rate 0f fibrinolysis was linear for up to 2 h, but was 
not quite linear with concentration of pure elastase or leukocyte extracts. We have therefore used 
the  2-h  values  for  comparing different  samples,  and  have related  these to  a  standard  curve 
obtained by measuring the activity of known amounts of pure elastase under identical conditions. 
We note that the specifc enzymatic activity of leukocyte preparations may vary, depending upon 
the purity of PMNs and erythrocyte contamination, and this accounts for the difference in specific 
activity  of  PMNs  from  normal  subjects  in  the  present  work,  compared  with  that  reported 
previously (9).  Finally, crude leukocyte lysates inhibit somewhat the activity of pure elastase, so 
that the addition of pure enzyme to cell extracts yields values that are not fully additive; the 
shortfall being ~30%.  We do not know whether this is due to inactivating enzymes, to specific 
elastase inhibitors, or to substrate competition between leukocyte protein and ~25I-fibrin. 
Results 
Human  PMNs  contain  several  proteases  that  are  catalytically  active  at 
neutral pH, including collagenase (12), plasminogen activator (9), a chymotryp- 
sin-like  enzyme  (13),  and  elastase  (14).  When  human  PMNs  are  lysed and 
assayed with  ~25I-fibrin as substrate  in the  absence of plasminogen,  the main 
source of proteolysis is elastase.  In fact, the plasminogen-independent  fibrino- 
lytic activity of human  leukocyte lysates is a  measure of their elastase (9),  as 
suggested by the following evidence: (a) the activity is resistant to trypsin and 
chymotrypsin inhibitors  and it is inhibited more than  85% by N-acetyl-(Ala)4- 
chloromethylketone (5 × 10  -3 M), a specific inhibitor ofelastase; (b) the activity 
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Fro. I.  Identifcation  of proteases  after SDS-PAGE  of lysates off (A) human  blood 
leukocytes, and  (B) mouse  peritoneal exudate  leukocytes. Lysates were prepared  as 
described  in  Materials and  Methods, electrophoresed  in  SDS-11% polyacrylamide  slab  gels, 
and  the  gels  were processed for  detection  of  fibrinolytic  activity  using a fibrin-agar  gel (9), 
in the absence of plasminogen.  The figure is a photograph of the amido-black-stained 
fibrin-agar  layer;  the clear  areas are due to lysis  of  fibrin  in the agar gel by proteases 
diffusing  out of  the polyacrylarnide  gels.  Parallel  lanes containing lysates  of  CHS  blood 
leukocytes or  beige mouse peritoneal  exudate leukocytes did  not show any zones  of  lysis. 
28,000-35,000, corresponding to those reported for purified  human  leukocyte 
elastase  (14);  (c)  when assayed using fibrin-agar  gels  (9),  elastase  is  the major 
neutral protease detected in lysates  of unfractionated leukocytes from blood 
(Fig. 1  A). 
Murine leukocyte lysates  also  contain a single  major neutral protease when 
assayed  on  fibrin-agar  gels  (Fig.  1  B). In  tool  wt ~27,000 this  enzyme is  close  to 
human elastase, and, like elastase, it is a serine protease inhibited 92% by di- 
isopropyl-fluorophosphate (10  -4 M) and 87% by soybean trypsin inhibitor  (100 
~tg/ml).  However,  unlike  elastase,  it  is  resistant  to  N-acetyl-(Ala)4-chloro- 
methylketone; it is also resistant to the trypsin inhibitors N-a-p-tosyl-L-lysine 
chloromethyl ketone  (10  -3  M) and nitrophenyl-p-guanidinobenzoate (10  -4  M). 
The chymotrypsin inhibitors L-l-tosylamide-2-phenylethyl-chloromethyl  ketone 
(10  -3 M) and N-carbobenzoxy-L-phenylalanine chloromethyl ketone (10  -3 M) re- 
duced this activity by somewhat less than 50%. Thus, this enzyme is a  serine 
protease of the pancreatic type,  but its precise substrate specificity, while in 
part chymotryptic, remains incompletely defined. 
We have tested lysates of buffy coats from CHS patients,  and of peritoneal 1288  VASSALLI  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE I 
Elastase in Lysates  of Human Leukocytes 
Elastase 
CHS case no.  (units per lO  s  PMNs  × I0  3) 
1  <0.i 
2  0.2 
3  <0.1 
Normal (range)  3.2 (1.5-5.6) 
Human  leukocytes were prepared,  lysed,  and assayed for fibrinolytic activity,  and the values 
obtained were related to standard preparations of purified elastase, as described in Methods. 
The elastase content of normal leukocytes was determined by assaying cells  from six control 
subjects (two adults and four children). 
exudates from beige mice both by the gel method (Fig. 1), and by measuring the 
solubilization of 125I-fibrin. In the gel system elastase was undetectable, and no 
other plasminogen-independent  activity  was present  in  human  CHS  lysates; 
likewise, the corresponding murine protease (of Fig. 1 B) was absent in lysates 
of beige  mouse  peritoneal  leukocytes.  When  assayed with  125I-fibrin  as  sub- 
strate,  plasminogen-independent  fibrinolysis was undetectable in lysates from 
two  CHS  patients,  whereas  the  third  patient,  clinically  the  least  affected, 
contained less than  10% of the normal level (Table I).  Comparable results for 
mice are  presented in  Table II,  and these show that  lysates from beige mice 
contain at most 3% of the neutral protease activity found in control strains. 
It is unlikely that the reduced activity in either of the affected cell extracts is 
due to excess inhibitors.  Mixtures  of inactive  and  active  extracts  gave  some 
reduction  of the  expected level,  but this was slight  (35%).  More importantly, 
however,  we  have  found  that  all  catalytically  inactive  complexes  formed 
between proteases and macromolecular inhibitors  so far tested are dissociated 
during SDS-PAGE, allowing the protease to be visualized by the gel method of 
Fig.  1 (A.  Granelli-Piperno  and E.  Reich, unpublished observations).  Were an 
inactive enzyme-inhibitor complex the explanation for our findings, some active 
bands should  have been detected in the gels.  Although  we cannot rigorously 
exclude excess inhibitor as the basis of our observations, such a  mechanism is 
not the most probable one. 
Discussion 
Despite the  limitations  of the  procedures  noted in  Materials  and  Methods, 
our results leave little doubt that  CHS leukocytes are profoundly deficient in 
elastase, and that an analogous deficiency occurs in beige mice. Moreover, since 
elastase is localized in  azurophile  granules,  our findings  provide  a  satisfying 
correlate for the morphological abnormality of these granules both in CHS and 
in beige mice.  While no cause and effect relationships  between the enzymatic 
and morphological changes can be deduced at present,  it will be of interest to 
determine whether or not specific enzyme deficiencies are associated with the 
granule  alterations  in  other  tissues.  Since  the  enzyme  deficiency  we  have 
observed could arise  from failure to activate proenzymes,  or from irreversible 
enzyme inactivation during granule formation,  it would also be useful to assay 
CHS and beige mouse leukocytes for substances that might be immunologically 
cross-reactive with their respective missing enzymes. 
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TABLE II 
Proteolytic Activity of Lysates of Mouse Peritoneal Cells 
Strain 
Substrate  solubilized  by lyeates from: 
3 × 104 Cells  1 × 10  ~ Cells 
BALB/cJ  4.7  37 
NCS  1.9  31 
C57 BL/6J, +/+  2.4  33 
C57 BL/6J, bg/bg  0.1  2.3 
Peritoneal  cells from endotoxin-injected mice were lysed and aSsayed for fibrinolytic  activity aS 
described in Materials and Methods. 
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affected and experienced numerous infections; all of their PMNs had abnormal 
granules, and their leukocyte elastase was undetectable. A third patient (case 
no.  2)  had  a  clinically milder form of the disease;  abnormal granules  were 
present only in a fraction of her PMNs, and her level of elastase was very low, 
but detectable. Hence, severity of disease, proportion of morphologically affected 
PMNs, and levels of leukocyte elastase appear to be correlated; it will be useful 
to test this correlation in a larger series of CHS patients. 
The increased susceptibility of CHS patients to infections has been linked to 
the impairment of leukocyte function, and the reported defects in bactericidal 
capacity of PMNs from CHS patients (4) and beige mice (5) might be significant 
pathogenetic factors. Since normal phagocytic rate and capacity of PMNs are 
retained in  these  disorders  (15,  5),  the reduced bactericidal  activity is  more 
likely due to a  defective intracellular killing mechanism. The possibility that 
elastase  deficiency might  introduce  a  rate  limitation  in  the killing  of some 
bacteria is attractive, because the peptidoglycan structure of organisms such as 
S. aureus contains an elastase-sensitive bond (16), and because this enzyme can 
lyse the cell walls of autoclaved S. aureus  (16), a pathogen that CHS PMNs kill 
inefficiently (4),  and  to  which these  patients  are  specially susceptible  (17). 
While not by itself bactericidal in vitro (16), elastase potentiates the activity of 
granulocyte  microbicidal  systems  against  E.  coli  and  S.  aureus  (18),  and 
participates in the digestion of E. coli  proteins in human PMNs (19); elastase 
might therefore be essential for normal rates of intracellular killing. 
Summary 
Peripheral blood leukocytes of  three patients with Ch~diak-Higashi syndrome 
(CHS) contained very low or undetectable levels of elastase, the major neutral 
protease in these cells.  Likewise, peritoneal exudate leukocytes of beige mice 
(the murine counterpart of CHS) contained correspondingly reduced levels of 
their major neutral protease,  a  serine enzyme of mol wt 27,000.  The elastase 
deficiency in CHS polymorphonuclear leukocytes might account in part for the 
high incidence of infections in these patients. 
We thank  Ms. Anne  McGinley, Ms. Virginia Iliescu, and Mrs. Atsuko  Horiuchi for their excellent 
technical assistance, and Dr. J.  Oliver for stimulating  discussions and generous gift of beige mice. 
Received for publication I  November 1977. 1290  VA$SALLI  ET  AL.  BRIEF  DEFINITIVE  REPORT 
References 
i.  Blume,  R.  S.,  J.  M.  Bennett,  R.  A.  Yankee,  and  S.  M.  Wolff.  1968. Defective 
granulocyte  regulation  in  the  Ch6diak-Higashi  syndrome.  N.  Engl.  J.  Med. 
279:1009. 
2.  Kimball, H. R.,  G. H. Ford,  and S.  M.  Wolff.  1975. Lysosomal enzymes in normal 
and Ch6diak-Higashi blood leukocytes. J. Lab. Clin. Med. 86:616. 
3.  Clark,  R.  A.,  and  H.  R.  Kimball.  1971. Defective granulocyte chemotaxis in the 
Ch6diak-Higashi syndrome. J. Clin. Invest. 50:2645. 
4.  Root,  R.  K.,  A.  S.  Rosenthal,  and  D.  J.  Balestra.  1972. Abnormal bactericidal, 
metabolic,  and  lysosomal functions  of Ch6diak-Higashi  syndrome leukocytes.  J. 
Clin. Invest. 51:649. 
5.  Gallin, J. I., J. S. Busak, E. Patten, and S. M. Wolff.  1974. Granulocyte function in 
the Ch6diak-Higashi syndrome of mice. Blood. 43:201. 
6.  Padgett,  G. A., R. W. Leader, J. R. Gorham, and C.  C. O'Mary. 1964. The familial 
occurrence of the Ch6diak-Higashi syndrome in mink and cattle. Genetics. 49:505. 
7.  Kramer,  J.  W.,  W.  C.  Davis,  and  D.  J.  Prieur.  1975. An  inherited  condition  of 
enlarged  leukocytic  and  melanin  granules  in  cats:  probable  homology with  the 
Chediak-Higashi syndrome. Fed. Proc. 34:861. 
8.  Taylor, R. F.,  and R. K. Farrell.  1973. Light and electron microscopy of peripheral 
blood neutrophils in a  killer whale affected with Ch6diak-Higashi syndrome. Fed. 
Proc. 32:822. 
9.  Granelli-Piperno,  A.,  J-D.  Vassalli,  and E.  Reich.  1977. Secretion of plasminogen 
activator by human polymorphonuclear leukocytes. Modulation  by glucocorticoids 
and other effectors. J. Exp. Med.  146:1693. 
10.  Dewald,  B.,  R.  Rindler-Ludwig,  U.  Bretz,  and  M.  Baggiolini.  1975. Subcellular 
localization  and heterogeneity of neutral  proteases in neutrophilic polymorphonu- 
clear leukocytes. J. Exp. Med.  141:709. 
11.  Quie,  P.  G., J.  G.  White,  B.  Holmes, and R.  A.  Good.  1967. In vitro bactericidal 
capacity of human  polymorphonuclear leukocytes:  diminished  activity  in  chronic 
granulomatous disease of childhood. J. Clin. Invest. 46:668. 
12.  Ohlsson,  K.,  and  I.  Olsson.  1973. The neutral  proteases  of human  granulocytes. 
Isolation  and  partial  characterization  of two  granulocyte  collagenases.  Eur.  J. 
Biochem. 36:473. 
13.  Rindler-Ludwig,  R.,  and  H.  Braunsteiner.  1975. Cationic  proteins  from  human 
neutrophil granulocytes: evidence for their chymotrypsin-like properties. Biochim. 
Biophys. Acta. 379:606. 
14.  Ohlsson,  K.,  and  I.  Olsson.  1974. The neutral  proteases  of human  granulocytes. 
Isolation and  partial  characterization  of granulocyte elastases.  Eur.  J.  Biochem. 
42:519. 
15.  Stossel, T.  P.,  R.  K. Root, and M.  Vaughan.  1972. Phagocytosis in chronic granu- 
lomatous disease and the Ch6diak-Higashi syndrome. N. Engl. J. Med. 286:120. 
16.  Janoff,  A.,  and  J.  Blondin.  1973. The  effect  of human  granulocyte  elastase  on 
bacterial suspensions. Lab. Invest. 29:454. 
17.  Blume, R. S., and S. M. Wolff.  1972. The Chediak-Higashi syndrome: studies in four 
patients and a review of the literature. Medicine (Baltimore). 51:247. 
18.  Odeberg, H., and I. Olsson. 1976. Microbicidal mechanisms of human granulocytes: 
synergistic effects of granulocyte elastase and myeloperoxidase or chymotrypsin-like 
cationic proteins. Infect. Immun.  14:1276. 
19.  Blondin, J.,  and A. Janoff. 1976. The role of lysosomal elastase in the digestion of 
Escherichia coli proteins by human polymorphonuclear leukocytes. J. Clin. Invest. 
58:971. 